Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Company says Bio 100 strategy targets launching over 100 biosimilars by 2040. It aims to double net sales by 2035 and reach a core EBITDA margin above 30%, backed by vertical integration and regulatory streamlining.
Sandoz’s Bio 100 plans expand its biosimilar portfolio to over 100 assets by 2040, targeting more than doubling net sales by 2035 and a core EBITDA margin above 30%.
Bio100 plans to grow the biosimilar portfolio to over 100 by 2040 and target 80% LoE coverage. It targets mid- to high single-digit sales growth through 2030, doubling net sales by 2035 and core EBITDA margin above 30%.